Big orders, bigger dilutions: companies rewriting their balance sheets

KNR Constructions won a ₹3,361 crore coal-mining contract from SECL, its largest ever and worth 92% of its market cap. The eight-year deal locks in years of revenue but forces KNR out of its road-building comfort zone into mining execution, a fundamentally different risk. With margins already compressing on new HAM projects, the question is whether KNR can deliver mining economics at scale without bleeding into its existing order book.

Creative Newtech landed a ₹3,194.83 crore BSNL BharatNet order, larger than the company's entire annual revenue. The contract turns a small-cap IT trader into a serious infrastructure player overnight, but the risk profile shifts from winning work to executing a project bigger than the company itself. This is the kind of order that either builds credibility or burns it.

IFC has sold ₹14,400 crore worth of Federal Bank shares over seven months, cutting its stake by a quarter. This is not a portfolio rebalance. IFC is a marquee long-term investor, and a methodical exit of this scale from a large-cap private lender signals a reassessment of the thesis. For Federal Bank, losing one of its most visible institutional backers removes a vote of confidence that was priced into the stock.

Gujarat Themis Biosyn will dilute roughly 22% of itself through a QIP to fund its ₹1,300 crore acquisition of Japan's MicroBiopharm. The dilution covers most of the purchase price, turning a small-cap fermentation player into a specialized oncology APIs and gene-therapy company. Prior filings flagged the blank cheque on terms; now the number is on the table, and existing shareholders are paying for the bet in equity.

Affle's promoters placed their entire 54.91% stake under a non-disposal undertaking with two global banks. This is not a pledge in the traditional margin-call sense, but it restricts the promoters' ability to freely sell or transfer stock. The move raises questions about what financial commitments sit behind the company's recent ₹1,100 crore preferential warrant issue, and whether the promoters' flexibility is now subordinated to lender terms.

Can Fin Homes is raising ₹5,000 crore in debt, equal to 46% of its market capitalisation. For a mid-cap housing financier, this is not routine refinancing; it is a bet on a materially larger loan book. The capital will expand lending capacity but also double down on the company's use at a time when housing credit growth is moderating. Balance-sheet discipline is the open question.

Parmax Pharma raised ₹19.28 crore through a preferential issue, more than its entire ₹18 crore market cap, handing control to 14 new investors. This follows a 57% revenue crash and an auditor flagging the MD's use of company funds. The fundraise is a takeover in all but name, executed from a position of deep distress. The governance issues flagged in prior filings have not been fixed; they have been handed to a new set of owners.

JNK India won an incinerator package for ADNOC's TA'ZIZ Salt Project worth ₹100-300 crore, landing at 12-36% of last year's ₹838 crore revenue. The deal validates JNK's international credibility in a segment where Indian EPC players are still building track records. With a December 2027 delivery timeline, the revenue impact stretches across multiple fiscals, and the order adds to an already strong export pipeline.

Dynacons Systems won a ₹125.88 crore AI and cloud infrastructure contract from Central Bank of India, its third major public-sector mandate after RBI and J&K Bank. The five-year deal is 8.8% of FY26 revenue and confirms a pattern: state-owned banks are outsourcing their AI and cloud stack build-out, and Dynacons is becoming the default integrator. The order book now provides clear revenue visibility for two years.

ACRE, the entity managing VISA Chrome's restructured debt, seized 16.3% of the company's equity from the promoter through a forced pledge invocation. This is not a voluntary sale; it is a concrete step toward resolving a company whose headline ₹1,050 crore profit last year came entirely from a one-time debt restructuring gain. The auditor's going-concern flag remains. A forced change in ownership structure is the next chapter of a story the promoter could not write on their own.

Kovai Medical Center's Joint MD Dr. Thavamani Devi Palaniswami died suddenly on June 6, leaving no named successor. She was both a top executive and a promoter, tying operational vision directly to ownership. For a hospital chain where leadership continuity matters for patient care and strategy, the immediate void creates uncertainty about direction until a succession plan emerges.

Vivo Bio Tech's promoter sold 99% of its stake, disposing of virtually its entire holding in a single trade. The company recently posted a ₹5.44 crore Q4 loss with auditors flagging overdue statutory dues, and proposed merging a resort company into itself. A promoter exit of this scale, in a nano-cap with thin liquidity, is not a portfolio adjustment. It is a signal.

Panth Infinity is acquiring a target for ₹97.65 crore in a share-swap deal, 1.6 times its own ₹61 crore market cap. The company is pivoting from trading into agriculture and animal nutrition through a transaction that dwarfs its existing balance sheet. Previous filings showed most warrant buyers walked away last time Panth Infinity went to market. This deal now has to close on credibility that has already been tested.

The government is selling up to 3% of NLC India through an offer for sale at a ₹303 floor price, worth roughly ₹1,260 crore. The sale adds meaningful liquidity to a stock whose free float is already dominated by state holdings. For a power company in the middle of a nuclear energy JV with NPCIL, the disinvestment is a clean valuation benchmark but not a strategic signal.